Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Maple Leaf HIFU is a specialized Canadian healthcare provider and the exclusive distributor of Ablatherm High-Intensity Focused Ultrasound (HIFU) technology in Canada. Established in 2005, the company focuses on providing minimally invasive, non-surgical treatment options for patients with localized prostate cancer. Operating out of locations such as Cleveland Clinic Canada in Toronto, Maple Leaf HIFU utilizes advanced robotic HIFU technology to target and destroy cancerous prostate tissue while minimizing side effects like incontinence and impotence. The company serves patients from across North America and is recognized as a pioneer in the clinical application of HIFU for urological oncology in the region. Its clinical team is led by experienced urologists who were among the first to adopt visually directed HIFU protocols in North America.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Maple Leaf HIFU.